When the next patient asks me about a game-changing HIV prevention tool, I hope I can say, "It's already here and available ...

A new chemical compound has been making a big impression in the fight against cancer in recent years. Now it seems EBC-46, otherwise known as tigilanol tiglate, may also have immense potential for ...

Obeldesivir is a relatively new antiviral drug with a broad spectrum of potential uses and also is being tested in clinical ...

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro ...

We recently published a list of 10 AI News and Ratings You Should Not Miss. In this article, we are going to take a look at ...

Cognizant and Gilead expand partnership to drive greater value through advanced technology applications: Teaneck, New Jersey Friday, January 31, 2025, 14:00 Hrs [IST] Cognizant ha ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...